新利18是什么东西|新利18是正规平台吗

Skip to content THE SOURCE Close TopicsTopics Arts & Culture Business & Entrepreneurship Campus & Community Humanities & Society Medicine & Health Science & Technology SchoolsSchools Arts & Sciences Brown School McKelvey School of Engineering Olin Business School Sam Fox School of Design & Visual Arts School of Continuing & Professional Studies School of Law School of Medicine PublicationsPublications Newsroom The Record Washington Magazine Search Menu Search for: Search Close NEWSROOM Sections Find an Expert Media Resources Newsroom Stories Perspectives WashU Experts WashU in the News New model of irregular heartbeat could boost drug efficacy Engineers use math to help to improve patient outcomes By Beth Miller October 29, 2019 SHARE Jonathan Silva, a biomedical engineer in the McKelvey School of Engineering at Washington University in St. Louis, has developed the first computational model that shows the molecular groundwork of a popular drug’s effectiveness in a variety of ways. (Credit: Jonathan Silva) Patients with irregular heartbeats, or arrhythmia, have few effective treatment options — available drugs are not always effective, and an implanted defibrillator can be too aggressive. Jonathan Silva, associate professor of biomedical engineering in the McKelvey School of Engineering at Washington University in St. Louis, has developed the first computational model that shows the molecular groundwork of a popular drug’s effectiveness in a variety of ways. The findings were published Oct. 28 in the Journal of the American College of Cardiology: Basic to Translational Science. Silva Current treatment for arrhythmia is the drug mexiletine, which is designed to block extra current that travels through the sodium channel in the heart that causes it to beat too fast, too slow or irregularly. However, the drug is not effective for every patient, though researchers are not clear why. Silva’s new model provides some answers. “What we found is that it doesn’t work because part of the channel is getting in the way,” he said. “What this study allowed us to do is use a computational model to give us insight to say if we pull that part (of the channel) out of the way, then the drug can come in and do its job.” The team used a model with two genetic mutations that cause arrhythmia in patients with long QT type 3 syndrome. One of the mutations, R1626P, allows the drug to work, while the other, M1652R, changes the channel to impede the drug’s access and makes the channel insensitive to the drug. Silva’s team is the first to use mathematical equations that show how the movements in the sodium channel open and close, and how those movements control where the drug blocks. Their model showed that this shift in the voltage sensing domain is critical for the drug to be effective. “That mathematical description at the molecular level then lets us take that and put it into a higher-level model and not only understand how those molecular movements affect the channel opening and closing,&＃8221; Silva said, &＃8220;as well as how the myocyte fires, how the arrhythmia happens and how drugs can prevent an arrhythmia.&＃8221; Silva and the team then put the model into practice to develop another model of a “booster” that made mexiletine perform better at reducing the amount of current coming through the sodium channel, even in the genetic mutation that does not allow the drug to work. Theoretically, administering this booster along with the drug to patients with arrhythmia would reduce or even stop the arrhythmia triggers. Silva said the findings extend beyond patients with Long QT Syndrome to patients with arrhythmias from other causes. “We propose that combination therapy with common pore blockers, enhanced by allosteric channel modulation could dramatically alter the landscape for antiarrhythmic therapy by adding an additional dimension to the parameter space of drug efficacy,” Silva said. “This would expand the number of patients who would receive clinical benefit from existing therapeutics and allow for a lower concentration of drugs to be used, decreasing off-target side effects.” The work builds on previous research by Silva and his team to investigate the efficacy of mexiletine on patients with Long QT Syndrome Type 3, during which they found that the Domain III voltage-sensing domain was correlated to the drug’s effect. The McKelvey School of Engineering at Washington University in St. Louis focuses intellectual efforts through a new convergence paradigm and builds on strengths, particularly as applied to medicine and health, energy and environment, entrepreneurship and security. With 96.5 tenured/tenure-track and 33 additional full-time faculty, 1,361 undergraduate students, 1,291 graduate students and 21,000 alumni, we are working to leverage our partnerships with academic and industry partners — across disciplines and across the world — to contribute to solving the greatest global challenges of the 21st century. Moreno J, Zhu W, Mangold K, Chung W, Silva J. A molecularly detailed Nav1.5 model reveals a new class I antiarrhythmic target. Journal of the American College of Cardiology: Basic to Translational Science. October 2019, Volume 4, Issue 6. 10.1016/j.jacbts.2019.06.002. This research was supported by the National Institutes of Health (R01-HL136556 and 5 T32 HL 7081-42). SHARE Media Contact  Brandie Jefferson FEATURED WASHU EXPERTS Jonathan SilvaProfessor of Biomedical Engineering TopicsEngineeringMedicine & HealthScience & Technology Schools McKelvey School of EngineeringRead more stories from McKelvey School of EngineeringVisit McKelvey School of Engineering Leave a Comment Comments and respectful dialogue are encouraged, but content will be moderated. Please, no personal attacks, obscenity or profanity, selling of commercial products, or endorsements of political candidates or positions. We reserve the right to remove any inappropriate comments. We also cannot address individual medical concerns or provide medical advice in this forum. You Might Also Like WashU-developed holograms help physicians during cardiac procedure July 20, 2020 Published In Newsroom Stories A sodium surprise July 20, 2017 Published In Newsroom Stories Edging closer to personalized medicine for patients with irregular heartbeat December 19, 2018 Published In Newsroom Stories Latest from the Newsroom Recent Stories Reframing voting as ‘duty to others’ key to increasing engagement, turnout Modifying homes for stroke survivors saves lives, extends independence Book explores consequences of political conversations WashU Experts Ten Commandments display probably not legal Social workers key to psychedelic-assisted therapies DeFake tool protects voice recordings from cybercriminals WashU in the News NFL faces ‘Sunday Ticket’ lawsuit: Here’s what’s at stake for the league Transcript: Ezra Klein Interviews Yanna Krupnikov The brain has a waste removal system and scientists are figuring out how it works Publications Washington Magazine Newsroom Record Explore Bookshelf Video Gallery Connect Media Resources Contact Facebook Instagram ©2024 Washington University in St. Louis Go back to top